Noah Starkey, MD
Internal Medicine · Enfield, CTNPI 1376648345
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 1,380 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 53 manufacturers, the largest accounting for just 17.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $4,127 and has fallen 79.5% since, to $847 in 2024. Among internal medicine clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,380 payments — averaging $13.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Novo Nordisk$3K
- GSK$2K
- Lilly USA, LLC$1K
- AstraZeneca$1K
- Boehringer Ingelheim$863
- plus $7K from 47 others
What the payments were for
- Food & beverage$18,41799%
- Education$2171%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$18,634 in reported general payments places this provider in the 95th percentile of 2,067 internal medicine providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 101 | $95,154 |
| JardianceEmpagliflozin | 56 | $75,064 |
| MounjaroTirzepatide | 46 | $56,579 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 41 | $54,083 |
| TrulicityDulaglutide | 34 | $49,123 |
| OzempicSemaglutide | 42 | $47,209 |
| EliquisApixaban | 41 | $42,034 |
| Xigduo XrDapaglifloz Propaned/Metformin | 23 | $29,432 |
| RybelsusSemaglutide | 19 | $29,356 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 25 | $27,757 |
| Repatha SureclickEvolocumab | 18 | $24,009 |
| JanuviaSitagliptin Phosphate | 19 | $23,079 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 13 | $20,359 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 16 | $18,514 |
| EdarbyclorAzilsartan Med/Chlorthalidone | 29 | $18,277 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $1,152 | $105,70280 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $863 | $102,82181 claims |
| AstraZenecaFarxiga | $1,145 | $95,154101 claims |
| Novo NordiskOzempic, Rybelsus | $2,821 | $76,56661 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $2,367 | $72,59757 claims |
| MerckJanuvia, Janumet Xr | $214 | $43,43732 claims |
| PfizerEliquis | $589 | $42,03441 claims |
| Johnson & JohnsonXarelto, Invokamet | $381 | $27,15224 claims |
| Arbor Pharmaceuticals, Inc.Edarbyclor | $549 | $18,27729 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $285 | $6,88613 claims |
| AbbVieSynthroid | $3,237 | $3,16644 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,067 internal medicine providers in Connecticut.
Other internal medicine in Enfield
- Steven RyderWestport$3.9M
- Nancy BrownNew Haven$1.6M
- Arthur DecillisMadison$1M
- Charles MontanoCromwell$970K
- Gary BlickNorwalk$683K
- Scott GottliebStamford$508K
- Jeffrey KatzOxford$361K
- Nicholas DainiakBridgeport$352K
- Thomas PellechiGreenwich$196K
- John PriceGlastonbury$188K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.